Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma

NCT05608291 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT05608291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05608291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 16, 2023
Completion date
April 3, 2030
Enrollment
1,564 (actual)
Sites
211

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma